Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients

Abstract. Whereas the molecular events underlying acute myeloid leukemia (AML) are increasingly identified, dynamics of hematologic recovery following induction chemotherapy remain mysterious. Platelet recovery may vary between incomplete and excess recovery among patients achieving remission. We an...

Full description

Bibliographic Details
Main Authors: Bianca R. Schnell, Katja Seipel, Ulrike Bacher, Barbara Jeker, Beatrice U. Mueller, Yara Banz, Urban Novak, Thomas Pabst
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000180

Internet

http://journals.lww.com/10.1097/HS9.0000000000000180

Similar Items